Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
| Autor: | Sai-Hong Ignatius Ou, Jeffrey W. Clark, Jared Weiss, D. Ross Camidge, Paul K. Paik, Mark A. Socinski, Alexander Drilon, Gregory J. Riely, Sherry C. Wang, Maria Winter, Keith D. Wilner, Katherine Monti |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Antitumor activity Oncology Cancer Research medicine.medical_specialty Pathology Lung Crizotinib business.industry non-small cell lung cancer (NSCLC) medicine.disease 03 medical and health sciences Exon 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Internal medicine Cohort medicine Adenocarcinoma In patient business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:108-108 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 108Background: MET alterations leading to exon 14 skipping occur in ~4% of lung carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro. Crizotinib, initially developed as a MET inhibitor, is currently approved for the treatment of ALK-positive NSCLC. We present crizotinib antitumor activity and safety data in pts with advanced MET exon 14-altered NSCLC. Methods: Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the ongoing phase I PROFILE 1001 study (NCT00585195) and received crizotinib at a starting dose of 250 mg BID. Responses were assessed using RECIST v1.0. Results: As of the data cut-off of Oct 30, 2015, 18 pts with MET exon 14-altered NSCLC had enrolled and 17 received treatment (15 response-evaluable, 2 not yet evaluable). Two pts discontinued treatment (1 due to an AE, 1 preferred another treatment formulation). Median age was 68 y (range 59−87). Tumor histology was as follows: 71% adenocarcinoma, 18% sarcomatoid adenocarcinoma, 6% adenosquam... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|